Yaacov, A., Grinshpun, A. (2026). <i>CBFB</i>
                    mutations as a predictive biomarker of endocrine therapy benefit in hormone receptor–positive (HR+) breast cancer: Discovery and validation in 3,799 patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1089